XM does not provide services to residents of the United States of America.
Q
Q

QIEN

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Qiagen NV Sees At Least $2 Billion Of Combined Annual Sales In 2028

BRIEF-Qiagen NV Sees At Least $2 Billion Of Combined Annual Sales In 2028 June 17 (Reuters) - Qiagen NV QIA.DE : QIAGEN NV - NEW 2028 TARGETS INCLUDES PLANS TO RETURN AT LEAST $1 BILLION TO SHAREHOLDERS FROM 2024-2028 QIAGEN NV SEES ABOUT 7% COMPOUND ANNUAL SALES GROWTH AT CONSTANT EXCHANGE RATES THROUGH 2024-2028 QIAGEN NV - HAS SET A GOAL FOR AT
Q

Qiagen eyes sales growth of 7% per year until 2028

Qiagen eyes sales growth of 7% per year until 2028 FRANKFURT, June 17 (Reuters) - Diagnostics company Qiagen QIA.DE said on Monday it was targeting 7% currency-adjusted sales growth per year until 2028 on lab testing machines for infections and cancer, as it maps out its post-pandemic strategy. Holding an investor event on Monday, it also issued a goal for adjusted operating income margin of at least 31% in 2028, up from 26.9% in 2023, by winding down unprofitable products and simplifying the or
Q

Evotec and Qiagen enter software collaboration for insights into multi-omics data

BRIEF-Evotec and Qiagen enter software collaboration for insights into multi-omics data June 3 (Reuters) - EVOTEC SE EVTG.DE : EVOTEC AND QIAGEN ENTER SOFTWARE COLLABORATION FOR BETTER INSIGHT INTO MULTI-OMICS DATA Further company coverage: EVTG.DE (Gdansk Newsroom)
Q

QIAGEN And Myriad Genetics Develop Distributable Homologous Recombination Deficiency Test

BRIEF-QIAGEN And Myriad Genetics Develop Distributable Homologous Recombination Deficiency Test May 31 (Reuters) - QIAGEN NV QIA.DE : SAID ON THURSDAY: QIAGEN AND MYRIAD GENETICS DEVELOP DISTRIBUTABLE HOMOLOGOUS RECOMBINATION DEFICIENCY TEST FOR GLOBAL RESEARCH AND COMPANION DIAGNOSTICS APPLICATIONS Further company coverage: QIA.DE (Gdansk Newsroom
Q

European futures point to another down day

LIVE MARKETS-European futures point to another down day Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com EUROPEAN FUTURES POINT TO ANOTHER DOWN DAY European stock futures pointed to a weaker start of trading on Thursday as uncertainty over the timing and scale of possible rate cuts in the United States keeps markets under pressure, erasing part of the May rally in global equities.
A
A
S
U
Q
B
M
E
I
S
U

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.